ampliphi biosciences
p.gif (verkleinert auf 52%)
mfg
p.gif (verkleinert auf 47%)
interessantes chartbild!! umsätze noch niedrig!
mfg
p.gif (verkleinert auf 47%)
The data to date suggests that the Phase 2b results in approx.18 months could be signficant enough to bring the MYDICAR, FDA Orphan status, to market, in 2015, without going to Phase 3 first.
Last weeks press release could be enough to push APHB to the $1 plus trading range. The upside annual royalty stream due to APHB for MYDICAR is well in excess of $100 mil. a year. Apply that multiplier/valuation to today's market cap. ($90 mil or so) and APHB would be trading many times today's current valuation, and that''s just based on MYDICAR, not Glybera or the significant upside of the biophage developing franchise. Plus US Army, Intrexon, and pending CF partner annoucement anytime now
mfg
18 mio zu 0,25$ nach 2wochen weg und kurs steht bei hohem volumen 0,40$
RICHMOND, Va. & COLWORTH, United Kingdom & SYDNEY--(BUSINESS WIRE)--
AmpliPhi BioSciences Corporation (APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company’s common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.
“We are very pleased to have the support of both existing and new life science investors”, said Philip J. Young, President and Chief Executive Officer of AmpliPhi. “The financing will allow us to accelerate development of the company’s bacteriophage-containing human therapeutics for use in the treatment of bacterial infections.”
Roth Capital Partners and Griffin Securities, Inc. served as placement agents for the offering.
The securities offered in this private placement transaction have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of a registration rights agreement entered into with the investors, the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock sold in the offering. Any offering of the Company’s securities under the resale registration statement referred to above will be made only by means of a prospectus.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
About AmpliPhi BioSciences
AmpliPhi BioSciences Corporation (APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics. The Company’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (XON), the U.S. Army and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com.
About Bacteriophages
Bacteriophages are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophages are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophages are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
Forward Looking Statements
To the extent that this press release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made, including without limitation the risk that bacteriophage-based therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. The Company does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.
p25162 • 7 hours ago
NYSE listing pending, SEC filing, 12-6-2013, 110,528,505 shares common stock outstanding
Recent SEC filing available to all coincided with $18 mil. stock sale, investor road show, APHB filed consolidated financials as of Sept 2013.. Ampliphi is reincorporating from a WA corporation to a Delaware corp. More importantly APHB appears to be seeking a New York Stock exchange listing to coincide with a reverse split (need to be above $4). This is very positive news for APHB shareholders. More liquidity, institutional investors & media exposure, etc. APHB has approx. $21 mil. is Stockholder equity as of today.
As of December 6, 2013, there were 110,528,505 shares of common stock outstanding and 8,859,978 shares of Series B Convertible Preferred Stock outstanding.
As of December 6, 2013, there were outstanding warrants to purchase the following shares of our capital stock:
Description # of shares subject to such Warrants Weighted-average exercise price of such Warrants
Common Stock 36,780,385 $ 0.15
As December 6, 2013, there were 25,721,000, shares of common stock subject to outstanding options.
On December 16, 2013, we entered into subscription agreements to issue an aggregate amount of approximately 72,003,000 shares of common stock for an aggregate purchase price of approximately $18 million as part of a private placement.
thefourthlaw • 5 hours ago
Richmond BizSense Article
With enough PR, maybe that split can be less than 1:10...
~~~~~~~~~~~~~~~~~
Firm’s pitch comes through loud and clear
MICHAEL SCHWARTZ JANUARY 2, 2014 0
Two capital raises in the past six months have an upstart local biotech firm feeling flush.
AmpliPhi Biosciences brought in $18 million in fresh cash in December. That followed $7 million it raised over the summer. The combined funds give the Glen Allen-based firm the firepower it needs to continue development of its bacteria-killing products into 2015.
“It’s giant,” Young said of the market potential for their products. “The global antibiotic market is estimated to top $40 billion by 2015. The numbers are huge.”
If and when they comes to market, AmpliPhi’s products would be delivered to patients in a variety of forms, including pills, inhalants and topical and intravenous applications.
The company will look to do clinical trials in 2014, although Young said patience is a virtue in the biotech industry. Getting a product to market is a long and complicated process of trial and error and regulatory red tape.
“You’ve got to be patient, but getting it going is exciting,” he said.
Its stock, which trades on the OTC Bulletin Board under the ticker symbol APHB, finished 2013 at $0.50 per share. The company hopes to move its stock to the New York Stock Exchange in the first quarter of 2014, Young said.
The two recent capital raises should last at least 18 months or so, but Young said AmpliPhi would continue its roadshow to get in front of investors.
“We’re never done,” he said. “I am very happy we got this money. But we’re never done meeting investors and talking to investors.
mfg
Nice find and post. To answer your earlier question about the reverse split ratio, I think it will be a minimum of what ever ratio gets APHB to at least $5 a share ($4 is required on NYSE for the listing) to attract institutional and mutual fund investors. Hopefully APHB is trading in the $1 plus range with today's share count by the time it sets the reverse split level ratio.
Buying APHB share today is like getting a Pre-IPO shares in a sense since APHB is not well known to the Street; however, once the NYSE listing is even announced, the exposure will attract $$ buyer based on the significant market potential and APHB leadership in Phage. That doesn't even consider their legacy royalty assets the will start producing revenue (Glybera) any day now. MYDICAR is even more significant even in the 3% to 5% new royalty range, potentially in the 2016 timeframe.
I like the fact that Phil is excited to continue spreading the Ampliphi word (their leadership position & addressable market) to new investors with road shows, and has positioned the company for NYSE listing. in Q.1/2014
Broadfin Healthcare Master Fund, Ltd. (Hedge) buys 14 Million APHB shares
Fantastic news for APHB on the Investor front with the recent hedge funds ($500 mil. under mgmt ) SEC filing,SC 13G on 1-3-2014, stating their recent 14 million APHB share purchase,, representing 7.67% of common. The share purchase price wasn't listed in the SEC filing.
I like the fact that APHB has raised an est. $30 mil. or so even in less than 6 months, even before they list on the NYSE in the coming months. It's highly likely we'll see significant upward movement in the share price before the NYSE listing with buyers getting in beforehand. Any significant Buy volume will move the stock up significantly based on the average daily trading volume. Less
mfg
ASX BIOTECH STOCKS SURGE 54% IN 2013
7th January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector.
These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and the S&P/ASX 200 Health Care Index which increased 23.5% for the calendar year and 79.9% over the past two years.
“Despite the strength in the sector many retail investors are still nervous when considering life sciences companies,” said Chief Investment Officer Matt McNamara.
“We’ve seen a surge of new listings in the US biotech scene with large price premiums and this sentiment is shared more among professional investors in Australia.”
BioScience Managers’ investment Alchemia Limited is one of a number of examples of biotech stocks well supported on the ASX in 2013, rising 48.1% to increase its market cap by $60 million.
Alchemia has been slowly building its market share for generic anti-coagulant fondaparinux since it received approval in 2011, establishing a $9.6 million profit share for FY2013. The company has imminent Phase III trial results for anti-cancer drug HA-Irinotecan while also establishing partnerships with Astra Zeneca and Merck Serono for earlier stage drug discovery programs during 2013.
Mobile health technology company iSonea Limited was another standout performer for the biotech sector, boasting a share price increase of 379% for the calendar year to lift its market cap to $88 million. In September this year iSonea launched the AirSonea wheeze monitoring device, its flagship product for asthmatics. The company has attracted business identity Bruce Mathieson as a cornerstone investor.
Adelaide-based drug developer Bionomics progressed a number of its programs targeting renal cancer, depression and anxiety as well as announcing a new partnership with Merck & Co targeting chronic pain. Bionomics had one of the most impressive increases in market cap in the sector, jumping $180m to finish the calendar year at $311m.
“These companies are well-known to those in the sector but are flying somewhat under the radar in the broader market,” commented Mr McNamara.
“Speculation is always there at this time of year regarding the potential for a breakout in the biotech sector. 2013 might go down as the year it turned the corner as we expect a strong year again for the sector in 2014 with product pipelines moving closer to commercialisation and a number of big pharma licensing deals.”
BioScience Managers Fund I remained in the top decile of Global PE/VC funds for FY2013, continuing to deliver a 26%+ net annual IRR and having returned $46 million as it enters its sixth year. Fund II has made six investments to date in AmpliPhi Biosciences Corp, Avita Medical , Nexus6 (NZ), Nexvet Biopharma, SeaDragon (NZ) and Rex Bionics (NZ) .
Phages & the Superbugs War
A specialist team of scientists from the University of Leicester has isolated viruses that eat bacteria - called phages - to specifically target the highly infectious hospital superbug Clostridium difficile (C. diff).
The future impact of antibiotics is dwindling at a pace that no one anticipated, with more and more bacteria out-smarting and 'out-evolving' these miracle drugs. This has re-energized the search for new treatments.
"One alternative to antibiotics is bacteriophages, known as phages, which unlike antibiotics, are specific in what they kill and will generally only infect one particular species, or even strain of bacteria, referred to as the 'host'. Following attachment to their hosts, they inject their DNA into the bacterium, which then replicates many times over, ultimately causing the bacterial cell to burst open. The phages released from the dead bacterium can then infect other host cells."
Dr. Clokie and her team have achieved the remarkable feat of isolating and characterizing the largest known set of distinct C. diff phages that infect clinically relevant strains of C. diff. Of these, a specific mixture of phages have been proved, through extensive laboratory testing, to be effective against 90% of the most clinically relevant C. diff strains currently seen in the U.K.
As a testament to their therapeutic potential, these phages, that are the subject of a patent application, have been licensed by AmpliPhi Biosciences Corporation, a US-based biopharmaceutical company and pioneers in developing phage-based therapeutics. AmpliPhi have already made progress in developing phages targeted against Pseudomonas aeruginosa, a pathogen that causes acute, life-threatening lung infections in cystic fibrosis patients. They were also the first biopharmaceutical company to demonstrate the effectiveness of Pseudomonas phages in controlled and regulated human clinical trials.
NYSE Listing coming - NOTICE OF SPECIAL MEETING OF SHAREHOLDER, Tuesday, February 11, 2014
Volume up significantly today and positive based on the pending NYSE and upcoming shareholder special meeting. Just with the announcement Ampliphi is already getting the Streets attention. Phil Young is doing a tremendous job as CEO since coming aboard in building shareholder value, raising awareness, partnering and this is just the beginning. Brought an approx. $5 mil. market cap company on the Pink Sheets a couple years ago to a $100 mil. plus market cap company with key partnerships. APHB's largest shareholder Intrexon is one of the hottest stocks on the NASDAQ in 2014.
1. PROPOSAL FOR APPROVAL OF MERGER AGREEMENT AND REINCORPORATION FROM WASHINGTON TO DELAWARE.
2. PROPOSAL FOR AUTHORIZATION OF THE REVERSE STOCK SPLIT.
3. PROPOSAL TO ENTER INTO THE INDEMNIFICATION AGREEMENTS.
4. PROPOSAL TO ADOPT AND ASSUME THE STOCK INCENTIVE PLAN
uniQure to pay APHB up to $4.9 in milestones, $100k annual fee, low single digital % net sales Royalties, FDA filing
Excerpt from uniQure's IPO SEC filing. APHB royalty stream to commence in first half of 2014 in EU. Also great new, they'll file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014
We have to date paid to AmpliPhi a one-time up-front payment of $1,750,000. We have agreed to pay AmpliPhi annual fees of $100,000, a total of $4,950,000 in development and regulatory milestone payments, and a royalty equal to a low single-digit percentage of net sales, if any, of licensed products sold by us or Chiesi.
We met with the Food and Drug Administration, or FDA, to discuss the regulatory pathway for Glybera in the United States, We plan to file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014.
von leytonorientfan
New analyst coverage : $1 price target
New analyst coverage of APHB last night from Roth Capital Partners, with a $1 target price...
I completely agree about the derisked nature of APHB's products, and the faster development timelines, but the valuation is further derisked by APHB's legacy investments/programs, which they don't mention:
"Roth starts AmpliPhi Biosciences at buy
February 13, 2014 by mcapraro ·
Roth Capital Partners has initiated coverage of AmpliPhi Biosciences (OTC:APHB) with a “buy” rating and price target of $1. The stock closed at 59 cents on Wednesday.
AmpliPhi is developing a validated approach, phage, to combat bacterial infections through its laser guided “smart bomb” approach to address this unmet medical need.
Phage are naturally occurring viruses that infect and kill bacteria but are benign and non-infective to eukaryotic human cells. They are abundant in the natural environment. Bacteriophage have been used for over a century throughout parts of the world as a treatment for bacterial infections, but have not been widely commercially developed for this purpose in the Western World due to the heavy reliance on antibiotics.
AmpliPhi is developing several bacteriophage therapies and has the platform in place to develop many more, writes analyst Joseph Pantginis.
“We see compelling value in AmpliPhi currently, namely because its products are early stage,” he said. “However, due to extensive historical use, we believe this is an unusually de-risked early-stage company.”
Mr. Pantginis figures the development programs at AmpliPhi could be accelerated due to both the unmet medical need and potentially faster development timelines. “We also believe that as the product candidates move forward the partnering potential is high,” he added."
I too agree 100% with your comment that analysts have yet to quantify the value of the legacy assets, especially Glybera since revenue and milestone payments start revenue flowing into APHB mid year 2014. I believe Roth would of at least doubled their price target if they knew this de-risked company had royalties and milestones coming in this year and for the foreseeable future.
The pending NYSE listing in Q.1 (expected) will have Buy Analysts lining up similar to Roth, and I expect with significantly higher price targets.
I too don't think the market and analysts haven't yet understood the significant upside valuation associated with APHB collaboration with Unilever PLC (NYSE: UL) to exploit novel genomic information to develop next generation, specific, natural antimicrobials for use in the personal care industry. Even though it's an early stage development effort, Unilever is a UK/Dutch based $110 billion market cap. multinational
mfg
Summary of last night's presentation
Excellent 20 minute presentation by the CEO last night - he stated that 2014 is a "major year" for APHB, and there will be "multiple value-driving events coming up this year".
Main points:
- APHB are "by far the leader in the world in developing bacteriophage"
- APHB have had "positive feedback" from both the FDA re the US Army programme for Staph.aureus and the MHRA re the pseudomonas programme
For 2014:
- 001 : this is the lead programme re pseudomonas and CF patients. A Phase 1 study will be initiated this year in the UK
- 002 : Staph.aureus/MRSA with the US Army. An in-human study will be initiated in Q3/Q4
- 004 : C.diff - data will be reported in the next few quarters
Endorsements/partnerships are ongoing with:
- Intrexon (working with APHB's R&D dept)
- University of Leicester in the UK
- Prince Charles Hospital, Brisbane
- Royal Brompton Hospital in the UK
- Institute Pasteur in Paris
- US Army (at Walter Reed Medical Centre)
The extensive patent portfolio covers:
- phages containing therapeutic agents
- sequential use of phage to enhance subsequent antibiotic application
- formulation and delivery
1
|